Function Mobilizes $750 Million to Redefine Women's Diagnostic Gap

Function is leveraging over $748 million of capital inflows to position itself as a disruptive force in the women's diagnostics market.

Capital Surge and Strategic Partnerships

After closing a $298 million Series B round, the company secured an additional $450 million from General Catalyst’s Customer Value Fund, a non‑dilutive source earmarked for scaling sales and marketing. In August, Function announced a research partnership with NYU Grossman School of Medicine to build AI‑driven early‑detection models for cancer, brain health, and cardiometabolic risk.

Diagnostic Data Highlights

■15% of female members exhibited thyroid antibodies 75‑times above normal despite normal TSH levels.

■7% showed a high‑risk triad of elevated hs‑CRP, Lp(a) and LDL cholesterol, a combination linked to increased cardiovascular risk in women.

■FSH levels doubled between members in their 20s and 30s, suggesting an earlier onset of perimenopause than clinical guidelines assume.

■20% of members had critically low ferritin (5 ng/mL) that prompted early colonoscopy referrals, bypassing standard age thresholds.

Market Dynamics and Competitive Edge

Function bundles hormone, cardiometabolic and immune biomarkers into a subscription model that goes beyond traditional lab panels. Its AI‑enhanced analytics use an individual’s own historical data as the reference point, delivering “personal baseline” insights rather than relying on population averages. This approach mitigates the risk of patients being billed for tests that insurers won’t cover and creates a premium offering for high‑income consumers seeking proactive health management.

Risk‑Reward Assessment

Regulatory uncertainty and data‑privacy concerns could constrain scaling, while the systemic under‑diagnosis of women’s health issues and rising digital‑health spend present a sizable growth tailwind. As longitudinal datasets mature, Function’s AI models may also find applications in clinical research and drug development, expanding revenue streams beyond direct‑to‑consumer diagnostics.

Bora Yalın – Senior Research Lead, International Capital Flows

Function’s fundraising success underscores that liquidity in health‑tech remains heavily driven by private‑equity capital. Yet its data‑centric, personalized diagnostic platform has the potential to disrupt the incumbent lab market. Investors should monitor regulatory developments and the quality of AI‑trained datasets as key variables in the risk‑on / risk‑off landscape.